课题基金 / 基金详情

Studies on HIV integrase inhibitors as key components of effective therapy: Molecular and pathogenesis studies

Studies on HIV integrase inhibitors as key components of effective therapy: Molecular and pathogenesis studies
HIV整合酶抑制剂作为有效治疗关键成分的研究：分子和发病机制研究
批准号：
177325
负责人：
Wainberg Mark A
金额：
$25.8万
依托单位：
CIUSSS de Centre-Ouest-de-l'Ile-de-Montral-Jewish General
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2008
资助国家：
加拿大
项目状态：
已结题
起止时间：
2008-09-01 至 2011-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=177325&lang=en
关键词：
Aids Antiviral Drug Cell Culture Human Immunodeficiency Virus Type 1 Immunoprecipitation In Vitro Translation Integrase Mutagenesis Northern Blot Real Time Pcr Reverse Transcriptase Transfection Virus Purification Western Blot

项目摘要

项目成果

Wainberg Mark A的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Highly Active Antiretroviral Therapy (HAART) has been successful in reducing HIV induced morbidity and mortality. A major problem is viral resistance to drugs included in therapy. To counteract this, and to best use current drugs, we must study the develo
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
What if HIV were unable to develop resistance against a new therapeutic agent?
Genetic signatures and functional phenotypes implicated in HIV-1 transmission and drug resistance
The Botswana-Canada AIDS Vaccine Discovery Partnership
The Botswana-Canada AIDS Vaccine Discovery Partnership
海外基金